Dr. Reddy`s Laboratories is currently trading at Rs. 2865.15, up by 6.50 points or 0.23% from its previous closing of Rs. 2858.65 on the BSE.The scrip opened at Rs. 2858.00 and has touched a high and low of Rs. 2920.00 and Rs. 2797.70 respectively. So far 8333 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.Last one week high and low of the scrip stood at Rs. 3187.00 and Rs. 2497.60 respectively. The current market cap of the company is Rs. 47856.73 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.Dr. Reddy`s Laboratories is planning to raise funds by issuance of Commercial Paper (CP). The meeting of company’s Board of Directors will be held on March 27, 2020 to consider and approve the same.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 2951.85, up by 53.75 points or 1.85% from its previous closing of Rs. 2898.10 on the BSE.The scrip opened at Rs. 2700.00 and has touched a high and low of Rs. 3187.00 and Rs. 2651.00 respectively. The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.Last one week high and low of the scrip stood at Rs. 3187.00 and Rs. 2497.60 respectively. The current market cap of the company is Rs. 48158.33 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.Dr. Reddy’s Laboratories has launched Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (USFDA). This product is the only ABrated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. The company’s Pyrimethamine Tablets USP, are available in 25 mg dose in bottle count sizes of 30 and 100. The Daraprim (pyrimethamine) brand had U.S. sales of approximately $10 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy’s Laboratories is currently trading at Rs. 2834.40, up by 8.00 points or 0.28% from its previous closing of Rs. 2826.40 on the BSE.The scrip opened at Rs. 2800.00 and has touched a high and low of Rs. 2902.00 and Rs. 2800.00 respectively. So far 12898 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.Last one week high and low of the scrip stood at Rs. 3083.00 and Rs. 2589.85 respectively. The current market cap of the company is Rs. 47791.92 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.Dr. Reddy`s Laboratories has launched Ziprasidone Mesylate for Injection, 20 mg (base)/ml Single-dose Vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/ml, approved by the U.S. Food and Drug Administration (USFDA). According to IQVIA Health, the Geodon brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy’s Laboratories is currently trading at Rs. 3169.65, down by 11.10 points or 0.35% from its previous closing of Rs. 3180.75 on the BSE.The scrip opened at Rs. 3050.00 and has touched a high and low of Rs. 3190.90 and Rs. 3050.00 respectively. So far 8589 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.Last one week high and low of the scrip stood at Rs. 3230.00 and Rs. 2878.40 respectively. The current market cap of the company is Rs. 52577.34 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.US Food and Drug Administration (USFDA) has completed audit at Dr. Reddy`s Laboratories’ API Manufacturing Plant-5 at Miryalaguda, Nalgonda District, Telangana. The company has been issued a Form 483 with 3 observations. The company will address them comprehensively within the stipulated timeline.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 3218.75, up by 21.20 points or 0.66% from its previous closing of Rs. 3197.55 on the BSE.The scrip opened at Rs. 3220.00 and has touched a high and low of Rs. 3238.85 and Rs. 3200.00 respectively. So far 11347 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3276.00 on 04-Feb-2020 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 3212.75 and Rs. 3115.00 respectively. The current market cap of the company is Rs. 53604.23 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.Dr. Reddy’s Laboratories has entered into a definitive agreement with Wockhardt to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs 1850 crore.The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr. Reddy`s along with related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees. The business undertaking is being transferred on a slump sale basis.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 3173.00, up by 12.20 points or 0.39% from its previous closing of Rs. 3160.80 on the BSE.The scrip opened at Rs. 3160.80 and has touched a high and low of Rs. 3184.00 and Rs. 3140.00 respectively. So far 28791 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3276.00 on 04-Feb-2020 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 3276.00 and Rs. 3100.00 respectively. The current market cap of the company is Rs. 52719.41 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.Dr. Reddy`s Laboratories has launched Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration (USFDA).The Syprine brand and generic product had U.S. sales or approximately $94.2 million MAT for the most recent twelve months ending in December 2019 according to IMS Health. The company’s Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles. Syprine is a trademark of Alton Pharma. Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys is currently trading at Rs. 3185.10, up by 157.05 points or 5.19% from its previous closing of Rs. 3028.05 on the BSE.The scrip opened at Rs. 3037.45 and has touched a high and low of Rs. 3201.95 and Rs. 3001.60 respectively. So far 106482 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 3201.95 on 27-Jan-2020 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 3201.95 and Rs. 3001.60 respectively. The current market cap of the company is Rs. 52763.45 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.Dr. Reddys Laboratories has reported a rise of 30.62% in its net profit at Rs 521.70 crore for the quarter ended December 31, 2019 compared to Rs 399.40 crore for the same quarter in the previous year. Total income of the company increased by 10.22% at Rs 3113.30 crore for Q3FY20 as compared Rs 2,824.50 crore for the corresponding quarter previous year.On the consolidated basis, the company has reported a net loss after taxes and share of profit of associates of Rs 538.40 crore for the quarter ended December 31, 2019 against net profit of Rs 500.30 crore for the same quarter in the previous year. However, total income of the company increased by 12.54% at Rs 4464.40 crore for Q3FY20 as compared Rs 3966.90 crore for the corresponding quarter previous year.

A fair growth of 11.43% in the revenue at Rs. 30440.00 millions was reported in the December 2019 quarter as compared to Rs. 27317.00 millions during year-ago period.Net Profit recorded in the quarter ended December 2019 rise to 30.62% to Rs. 5217.00  millions  compared to R. 3994.00 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 8250.00 millions from 7797.00 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 30440.00 27317.00 11.43 89987.00 79803.00 12.76 106255.00 93593.00 13.53 Other Income 693.00 928.00 -25.32 6174.00 2025.00 204.89 2384.00 2040.00 16.86 PBIDT 8250.00 7797.00 5.81 29646.00 20288.00 46.13 25381.00 15339.00 65.47 Interest 117.00 158.00 -25.95 360.00 481.00 -25.16 568.00 628.00 -9.55 PBDT 8133.00 7639.00 6.47 29286.00 19807.00 47.86 24813.00 14711.00 68.67 Depreciation 1958.00 1935.00 1.19 5969.00 5764.00 3.56 7806.00 7741.00 0.84 PBT 6175.00 5704.00 8.26 23317.00 14043.00 66.04 17007.00 6970.00 144.00 TAX 958.00 1710.00 -43.98 -1032.00 3298.00 -131.29 4234.00 1301.00 225.44 Deferred Tax -134.00 1276.00 -110.50 -5181.00 1137.00 -555.67 1416.00 -80.00 -1870.00 PAT 5217.00 3994.00 30.62 24349.00 10745.00 126.61 12773.00 5669.00 125.31 Equity 831.00 830.00 0.12 831.00 830.00 0.12 830.00 830.00 0.00 PBIDTM(%) 27.10 28.54 -5.05 32.94 25.42 29.59 23.89 16.39 45.75

Dr. Reddys Laboratories is currently trading at Rs. 2943.20, up by 73.05 points or 2.55% from its previous closing of Rs. 2870.15 on the BSE.The scrip opened at Rs. 2925.00 and has touched a high and low of Rs. 2945.00 and Rs. 2874.30 respectively. So far 16003 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 2990.00 on 27-Nov-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 2969.00 and Rs. 2850.00 respectively. The current market cap of the company is Rs. 48776.66 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.Dr. Reddy`s Laboratories has launched Bortezomib for Injection 3.5 mg/vial, approved by the US Food and Drug Administration (USFDA) via a 505(b) (2) new drug application (NOA) pathway for intravenous use only.The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 2882.65, up by 23.60 points or 0.83% from its previous closing of Rs. 2859.05 on the BSE.The scrip opened at Rs. 2860.00 and has touched a high and low of Rs. 2885.00 and Rs. 2859.40 respectively. So far 3181 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 2990.00 on 27-Nov-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 2982.45 and Rs. 2853.40 respectively. The current market cap of the company is Rs. 47821.23 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.Dr. Reddy`s Laboratories has launched Bortezomib for Injection 3.5 mg/vial, approved by the US Food and Drug Administration (USFDA) via a 505(b) (2) new drug application (NOA) pathway for intravenous use only.The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 2884.95, up by 13.45 points or 0.47% from its previous closing of Rs. 2871.50 on the BSE.The scrip opened at Rs. 2868.00 and has touched a high and low of Rs. 2892.00 and Rs. 2853.00 respectively. So far 8352 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 2902.00 and Rs. 2724.15 respectively. The current market cap of the company is Rs. 47868.25 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.Dr. Reddy’s Laboratories has launched Doxercalciferol Injection,4 mcg/2 ml (2 mcg/ml) multiple-dose vials, the therapeutic generic equivalent of Hectorol (doxercalciferol) injection 4 mcg/2 ml (2 mcg/ml) Multiple - Dose Vials, approved by the U.S. Food and Drug Administration (USFDA).The Hectorol injection 4 mcg/2 ml (2 mcg/ml) single-dose vials and multiple-dose vials brand and generics had U.S. sales of approximately $138 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health.Dr. Reddy`s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 2755.90, down by 26.95 points or 0.97% from its previous closing of Rs. 2782.85 on the BSE.The scrip opened at Rs. 2783.00 and has touched a high and low of Rs. 2829.00 and Rs. 2736.15 respectively. So far 56470 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.Last one week high and low of the scrip stood at Rs. 2829.00 and Rs. 2736.15 respectively. The current market cap of the company is Rs. 45651.87 crore.The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.Dr. Reddy`s Laboratories has reported around four-fold jump in its net profit at Rs 1,365.10 crore for the quarter ended September 30, 2019 as compared to Rs 346.20 crore for the same quarter in the previous year. Total income of the company increased by 30.19% at Rs 3,522.70 crore for Q2FY20 as compared Rs 2,705.80 crore for the corresponding quarter previous year. On the consolidated basis, the company has reported over two-fold jump in its net profit at Rs 1,106.80 crore for the quarter under review as compared to Rs 518.30 crore for the same quarter in the previous year. Total income of the company increased by 23.34% at Rs 4,866.80 crore for Q2FY20 as compared Rs 3,945.70 crore for the corresponding quarter previous year.